NCT00555841

Safety and Efficacy of ALC in Breast Cancer in Subjects With Fatigue

Safety and Efficacy of Oral Acetyl-l-carnitine (ALC) in Non-anemic Potentially Curable Breast Cancer Subjects Undergoing Adjuvant Radiation Therapy Who Have Moderate to Severe Fatigue

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 27 (actual)
• Sponsor: Sigma-Tau Research, Inc. · Industry
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The objective of this study is to evaluate the efficacy and safety of ALC in the treatment of non-anemic, breast cancer subjects who develop moderate or severe fatigue during adjuvant radiotherapy.

Detailed description

The objective of this study is to evaluate the efficacy and safety of ALC in the treatment of non-anemic, breast cancer subjects who develop moderate or severe fatigue during adjuvant radiotherapy

Conditions

• Breast Cancer

Interventions

Type	Name	Description
DRUG	ALC and Placebo	ALC and Placebo

Timeline

• Start date: 2007-03-01
• Primary completion: 2008-09-01
• Completion: 2008-09-01
• First posted: 2007-11-09
• Last updated: 2012-08-28

Locations

1 site across 1 country: United States